Allison Bratzel
Stock Analyst at Piper Sandler
(4.75)
# 83
Out of 5,090 analysts
48
Total ratings
71.05%
Success rate
22.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Overweight | $28 → $30 | $8.65 | +246.82% | 1 | Nov 11, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $820 → $930 | $901.17 | +3.20% | 15 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $26 → $35 | $35.00 | - | 3 | Nov 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $70 → $77 | $81.68 | -5.73% | 3 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $82 → $102 | $102.52 | -0.51% | 3 | Nov 4, 2025 | |
| IOBT IO Biotech | Maintains: Overweight | $10 → $3 | $0.70 | +330.60% | 1 | Oct 22, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $52 → $51 | $45.02 | +13.28% | 4 | Sep 24, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $70 → $112 | $114.51 | -2.19% | 1 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $10.61 | +107.35% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $21.50 | +53.49% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $115 | $36.38 | +216.11% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $6 | $1.54 | +289.61% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $8.07 | +222.18% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $48.92 | -52.98% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $20.97 | +4.91% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.23 | +225.20% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $5.77 | +246.62% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $3.56 | +461.80% | 1 | Oct 13, 2023 |
MeiraGTx Holdings
Nov 11, 2025
Maintains: Overweight
Price Target: $28 → $30
Current: $8.65
Upside: +246.82%
argenx SE
Nov 4, 2025
Maintains: Overweight
Price Target: $820 → $930
Current: $901.17
Upside: +3.20%
Travere Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $26 → $35
Current: $35.00
Upside: -
Ionis Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $70 → $77
Current: $81.68
Upside: -5.73%
Incyte
Nov 4, 2025
Maintains: Overweight
Price Target: $82 → $102
Current: $102.52
Upside: -0.51%
IO Biotech
Oct 22, 2025
Maintains: Overweight
Price Target: $10 → $3
Current: $0.70
Upside: +330.60%
Scholar Rock Holding
Sep 24, 2025
Maintains: Overweight
Price Target: $52 → $51
Current: $45.02
Upside: +13.28%
ABIVAX Société Anonyme
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $114.51
Upside: -2.19%
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $10.61
Upside: +107.35%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $21.50
Upside: +53.49%
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $36.38
Upside: +216.11%
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $1.54
Upside: +289.61%
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $8.07
Upside: +222.18%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $48.92
Upside: -52.98%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $20.97
Upside: +4.91%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.23
Upside: +225.20%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $5.77
Upside: +246.62%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $3.56
Upside: +461.80%